[1]张艳秋,王晓军,张 莹,等.2 型糖尿病并发骨质疏松患者血清Asprosin，MIP-1β 水平与骨密度及骨代谢指标的相关性[J].现代检验医学杂志,2024,39(05):135-139+145.[doi:10.3969/j.issn.1671-7414.2024.05.025]
　ZHANG Yanqiu,WANG Xiaojun,ZHANG Ying,et al.Correlation of Serum Asprosin，MIP-1β Levels with Bone Mineral Density and Bone Metabolism Indexes in Patients with Type 2 Diabetes Mellitus Combined with Osteoporosis[J].Journal of Modern Laboratory Medicine,2024,39(05):135-139+145.[doi:10.3969/j.issn.1671-7414.2024.05.025]
点击复制

2 型糖尿病并发骨质疏松患者血清Asprosin，MIP-1β 水平与骨密度及骨代谢指标的相关性()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第39卷
期数:
2024年05期
页码:
135-139+145
栏目:
论著
出版日期:
2024-09-15

文章信息/Info

Title:
Correlation of Serum Asprosin，MIP-1β Levels with Bone Mineral Density and Bone Metabolism Indexes in Patients with Type 2 Diabetes Mellitus Combined with Osteoporosis
文章编号:
1671-7414（2024）05-135-06
作者:
张艳秋; 王晓军; 张 莹; 刘 丹
（承德市中心医院内分泌科，河北承德 067000）
Author(s):
ZHANG Yanqiu;  WANG Xiaojun;  ZHANG Ying;  LIU Dan
（Department of Endocrinology, Chengde Central Hospital, Hebei Chengde 067000, China）
关键词:
白脂素; 巨噬细胞炎症蛋白-1β; 2 型糖尿病并发骨质疏松
分类号:
R587.2；R446.11
DOI:
10.3969/j.issn.1671-7414.2024.05.025
文献标志码:
A
摘要:
目的 探究2 型糖尿病并发骨质疏松患者血清白脂素（Asprosin）、巨噬细胞炎症蛋白-1β（macrophageinflammato-ry protein-1β，MIP-1β）水平与骨密度及骨代谢指标的相关性。方法 选取2022 年4 月～ 2023 年4 月在承德市中心医院就诊的172 例2 型糖尿病患者为研究对象，并根据骨密度值结果分为2 型糖尿病组（n=103）和2 型糖尿病并发骨质疏松组（n=69）；采用ELISA 法测定血清Asprosin，MIP-1β 水平；Pearson 法分析血清Asprosin，MIP-1β 表达水平与骨密度的相关性；Logistic 回归分析2 型糖尿病并发骨质疏松的影响因素；受试者工作特征（ROC）曲线分析血清Asprosin，MIP-1β 水平对2 型糖尿病并发骨质疏松的预测价值。结果 与2 型糖尿病组比，2 型糖尿病并发骨质疏松组患者血清β-CTX（0.48±0.08ng/ml vs 0.42±0.04ng/ml），Asprosin（2.26±0.56ng/ml vs 1.65±0.36ng/ml），MIP-1β（26.01±6.43pg/ml vs 19.46±4.27pg/ml） 水平均显著升高， 骨密度（0.67±0.13g/cm2 vs 0.84±0.17g/cm2），BGP（8.33±1.23ng/ml vs 9.54±1.42ng/ml），T-P1NP（30.38±3.27ng/ml vs 32.49±3.29ng/ml）水平降低，差异具有统计学意义（t=6.501，8.699，8.032，7.039，5.773，4.133，均P<0.05）；Pearson 法分析显示，2 型糖尿病并发骨质疏松组患者血清Asprosin，MIP-1β 水平均与骨密度呈负相关（r=-0.484，-0.498，均P<0.05）；Logistic 回归分析显示血清Asprosin，MIP-1β 水平均为影响2 型糖尿病并发骨质疏松发生的独立危险因素（均P<0.05）；ROC曲线分析显示，血清Asprosin，MIP-1β 水平预测2 型糖尿病患者并发骨质疏松的AUC 分别为0.768，0.704，联合预测的AUC 为0.859，优于二者单独预测（Z=1.812，2.895，均P<0.05）。结论 2 型糖尿病患者并发骨质疏松患者血清Asprosin，MIP-1β水平显著升高，二者水平与骨密度密切相关，血清Asprosin，MIP-1β 是2 型糖尿病发生骨质疏松的独立危险因素，二者联合检测对疾病发展有较高的预测价值。
Abstract:
Objective To investigate the correlation between serum Asprosin, macrophage inflammatory protein-1β (MIP-1β) levels and bone mineral density and bone metabolism indexes in patients with type 2 diabetes mellitus（T2DM）combined with osteoporosis. Methods A tatal of 172 patients with T2DM attending Chengde City Central Hospital from April 2022 to April 2023 were selected for the study, and they were divided into T2DM group (n =103) and T2DM combined with osteoporosis group (n=69) according to the results of bone mineral density. Serum Asprosin and MIP-1β levels were measured by ELISA. Pearson method was used to analyze the correlation between serum Asprosin, MIP-1β expression levels and bone mineral density. Logistic regression was used to analyze the factors affecting T2DM combined with osteoporosis, and the receiver operating characteristic (ROC) curve was used to analyze the predictive value of serum Asprosin and MIP-1β level on T2DM combined with osteoporosis. Results Compared with the T2DM group, patients in the T2DM combined with osteoporosis group had higher levels of serum β-CTX (0.48 ± 0.08ng/ml vs 0.42 ± 0.04ng/ml), Asprosin (2.26 ± 0.56ng/ml vs 1.65 ± 0.36ng/ml) and MIP-1β (26.01 ± 6.43pg/ml vs 19.46 ± 4.27pg/ml), while BMD (0.67 ± 0.13g/cm2 vs 0.84 ± 0.17g/cm2), BGP (8.33 ± 1.23ng/ml vs 9.54 ± 1.42ng/ml) and T-P1NP (30.38 ± 3.27ng/ml vs 32.49 ± 3.29ng/ml) levels were decreased, with statistically significant differences (t=6.501, 8.699, 8.032, 7.039, 5.773, 4.133, all P< 0.05). Pearson method analysis showed that serum Asprosin and MIP-1β levels were negatively correlated with bone mineral density of patients in the T2DM combined with osteoporosis group (r=-0.484，-0.498，all P<0.05). Logistic regression analysis showed that serum Asprosin and MIP-1β levels were independent risk factors influencing the occurrence of T2DM combined with osteoporosis (all P<0.05). ROC curve analysis showed that the AUCs of serum Asprosin and MIP-1β levels predicted T2DM combined osteoporosis were 0.768 and 0.704, respectively, and the AUC of both combined prediction was 0.859, which was better than the two alone (Z=1.812，2.895， all P<0.05). Conclusion Serum Asprosin and MIP-1β levels are elevated in patients with T2DM combined with osteoporosis, and both are closely related to bone mineral density. Serum Asprosin and MIP-1β are independent risk factors for the development of T2DM combined with osteoporosis, and the joint detection of the two tests may have high predictive value for the development of the disease.

参考文献/References:

[1] 吴振, 徐燕, 苏文韬, 等. 2 型糖尿病合并颈动脉粥样硬化患者血清甲状旁腺激素及25 羟维生素D 与糖脂代谢的相关性[J]. 实用临床医药杂志, 2022, 26(17):120-124. WU Zhen, XU Yan, SU Wentao, et al. Correlations of serum parathyroid hormone and 25 hydroxyvitamin D with glycolipid metabolism in patients with type 2 diabetes mellitus complicated with carotid atherosclerosis[J]. Journal of Clinical Medicine in Practice, 2022, 26(17): 120-124.
[2] 孙丽娜, 王星, 杜国慧. IGF-1，IGF-2 与2 型糖尿病合并骨质疏松症老年患者骨代谢指标的关系及其临床意义[J]. 临床和实验医学杂志, 2022, 21(20):2163-2167. SUN Lina, WANG Xing, DU Guohui. Relationship between IGF-1, IGF-2 and bone metabolic indexes in elderly patients with T2DM complicated with osteoporosis and its clinical significance[J]. Journal of Clinical and Experimental Medicine, 2022, 21(20): 2163-2167.
[3] 田晓虹, 朱瑛. 利拉鲁肽联合阿法骨化醇治疗老年2型糖尿病合并骨质疏松症患者的临床疗效及其对骨代谢和骨密度的影响[J]. 临床合理用药杂志, 2022,15(18): 97-100. TIAN Xiaohong, ZHU Ying. Clinical effect of liraglutide combined with alfacalcidol in the treatment of elderly patients with type 2 diabetes mellitus complicated with osteoporosis and its effect on bone metabolism and bone mineral density[J]. Chinese Journal of Clinical Rational Drug Use, 2022, 15(18): 97-100.
[4] 邓娜, 郭志新. 2 型糖尿病合并非酒精性脂肪性肝病患者血清白脂素和脂联素水平的变化及意义[J]. 胃肠病学和肝病学杂志, 2022, 31(10): 1101-1107. DENG Na, GUO Zhixin. Changes and significance of serum asprosin and adiponectin levels in type 2 diabetes mellitus patients with non-alcoholic fatty liver disease[J]. Chinese Journal of Gastroenterology and Hepatology, 2022, 31(10): 1101-1107.
[5] NAIEMIAN S, NAEEMIPOUR M, ZAREI M, et al. Serum concentration of asprosin in new-onset type 2 diabetes[J]. Diabetology & Metabolic Syndrome, 2020,12: 65.
[6] CHANG Tingting, LIN Liangyu, CHEN J W. Inhibition of macrophage inflammatory protein-1β improves endothelial progenitor cell function and ischemiainduced angiogenesis in diabetes[J]. Angiogenesis, 2019, 22(1): 53-65.
[7] 王强珍. 血清MIP-1β，TRACP-5b 和FGF-23 检测对绝经后骨质疏松患者发生骨折的预测价值[J]. 检验医学与临床, 2023, 20(1): 36-40. WANG Qiangzhen. Predictive value of serum MIP-1β, TRACP-5b and FGF-23 detection to fracture occurrence in patients with postmenopausal osteoporosis[J]. Laboratory Medicine and Clinic, 2023, 20(1): 36-40.
[8] 中华医学会糖尿病学分会. 中国2 型糖尿病防治指南(2013 年版)[J]. 中国糖尿病杂志, 2014, 22(8):2-42. Chinese Diabetes Society. Guidelines for prevention and treatment of type 2 diabetes in China (2013 version)[J]. Chinese Journal of Diabetes, 2014, 22(8): 2-42.
[9] 中华医学会骨质疏松和骨矿盐疾病分会. 原发性骨质疏松症诊疗指南(2017)[J]. 中国骨质疏松杂志,2019, 25(3): 281-309. Chinese Society of Osteoporosis and Bone Mineral Research. Guidelines for the diagnosis and management of primary osteoporosis(2017)[J]. Chinese Journal of Osteoporosis, 2019, 25(3): 281-309.
[10] 向省平, 刘琳, 陈艳, 等. 2 型糖尿病合并骨质疏松症患者血清N-MID，TP1 NP，β-CTX 水平与冠状动脉钙化的相关性[J]. 川北医学院学报, 2023,38(7): 985-988. XIANG Shengping, LIU Lin, CHEN Yan, et al. Correlation between serum N-MID, TP1NP β-CTX level and coronary artery calcification in type 2 diabetes patients with osteoporosis[J]. Journal of North Sichuan Medical College, 2023, 38(7): 985-988.
[11] 李晓, 徐群, 洪赛赛. 围绝经期2 型糖尿病患者雌激素水平及其对心血管疾病发病的影响[J]. 中国妇幼保健, 2022, 37(19): 3646-3649. LI Xiao, XU Qun, HONG Saisai. Estrogen level in perimenopausal patients with type 2 diabetes and its effect on cardiovascular disease[J]. Maternal and Child Health Care of China, 2022, 37(19): 3646-3649.
[12] 丁莉, 彭健韫, 张伟, 等. 血清miRNA-16 和miRNA-92a 在2 型糖尿病合并骨质疏松症患者中的表达及与骨代谢相关性研究[J]. 浙江医学, 2021,43(21): 2303-2307. DING Li, PENG Jianyun, ZHANG Wei, et al. Serum miRNA-16 and miRNA-92a expression in type 2 diabetic patients with osteoporosis and their correlation with bone metabolism[J]. Zhejiang Medical Journal, 2021, 43(21): 2303-2307.
[13] 汤小峰, 蒋艺兰, 朱蓓. 糖尿病性骨质疏松患者雌激素受体α 基因XbaI(rs9340799)SNP 和HbA1c 水平交互作用与疾病易感性分析[J]. 现代检验医学杂志,2023, 38(1): 38-43. TANG Xiaofeng, JIANG Yilan, ZHU Bei. Analysis of interaction between estrogen receptorα gene XbaI (rs9340799) SNP and HbA1c level and disease susceptibility in patients with diabetes osteoporosis[J]. Journal of Modern Laboratory Medicine, 2023, 38(1):38-43.
[14] GOODARZI G, SETAYESH L, FADAEI R, et al. Circulating levels of Asprosin and its association with insulin resistance and renal function in patients with type 2 diabetes mellitus and diabetic nephropathy[J]. Molecular Biology Reports, 2021, 48(7): 5443-5450.
[15] DENG Xia, ZHAO Zhicong, ZHAO Li, et al. Association between circulating Asprosin levels and carotid atherosclerotic plaque in patients with type 2 diabetes[J]. Clinical Biochemistry, 2022, 109–110: 44-50.
[16] 夏海娥, 陈鸿颜, 陈洪娇. 血清Asprosin 水平与绝经后女性骨密度、平衡能力和骨折发生率的相关性[J].中国骨质疏松杂志, 2021, 27(2): 208-211. XIA Haie, CHEN Hongyan, CHEN Hongjiao. The correlation between serum Asprosin levels and bone mineral density, balance ability and fracture incidence in postmenopausal women[J]. Chinese Journal of Osteoporosis, 2021, 27(2): 208-211.
[17] 上官海燕, 王亚梅, 周琪, 等. 血清IL-33，Asprosin水平与2 型糖尿病合并骨质疏松症的相关性[J]. 山东医药, 2023, 63(22): 17-20. SHANG GUAN Haiyan, WANG Yamei, ZHOU Qi, et al. Correlations between serum IL-33, Asprosin and type 2 diabetes mellitus combined with osteoporosis[J]. Shandong Medical Journal, 2023, 63(22): 17-20.
[18] 董苏薇, 韩秋峪, 孙亚薇, 等. 妊娠期糖尿病患者血清Asprosin，Metrnl 因子表达与糖脂代谢的相关研究[J]. 徐州医科大学学报, 2022, 42(12): 925-930. DONG Suwei, HAN Qiuyu, SUN Yawei, et al. Correlation between the expression of serum Asprosin and Metrnl and glucolipid metabolism in patients with gestational diabetes mellitus[J]. Journal of Xuzhou Medical University, 2022, 42(12): 925-930.
[19] 宋茜茜, 尹飞, 郭淑芹, 等. 2 型糖尿病合并骨质疏松症患者血清CX3CL1，CCL3，CCL4 与糖脂代谢、骨密度及骨代谢标志物的相关性[J]. 疑难病杂志,2022, 21(8): 828-833. SONG Qianqian, YIN Fei, GUO Shuqin, et al. Correlation of serum CX3CL1, CCL3, CCL4 with glucose and lipid metabolism, bone mineral density and bone metabolism markers in patients with type 2 diabetes and osteoporosis[J]. Chinese Journal of Difficult and Complicated Cases, 2022, 21(8): 828-833.
[20] CHANG Tingting, LIN Liangyu, CHEN J W. A novel resolution of diabetes: C-C chemokine motif ligand 4 is a common target in different types of diabetes by protecting pancreatic islet cell and modulating inflammation[J]. Frontiers in Immunology, 2021, 12: 650626.
[21] YANG Xianwen, WANG Fei, QIN Ruzi, et al. Elevated serum CCL4/MIP-1β levels in postmenopausal osteoporosis patients are linked with disease severity[J]. Biomarkers in Medicine, 2019, 13(1): 17-25.

备注/Memo

备注/Memo:
基金项目：河北省卫健委2021 年度医学科学研究课题项目（20211478）。
作者简介：张艳秋（1982-），女，硕士研究生，主治医师，研究方向：内分泌与代谢病，E-mail：zhangyq202308@126.com。
通讯作者：刘丹（1979-）女，本科，副主任医师，研究方向：内分泌方面疾病的诊断与治疗，E-mail：liu_dan1979@163.com。
更新日期/Last Update: 2024-09-15